Dr. Douglas S. Corwin, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 513
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
PA license MD461302 -
Critical Care Medicine (Internal Medicine) Physician
PA license MD461302 -
Internal Medicine Physician
MD license D75863
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Lukes Hospital Bethlehem, PA
- St Luke's Hospital - Upper Bucks Campus Quakertown, PA
- St Luke's Hospital - Monroe Campus Stroudsburg, PA
- St Luke's Miners Memorial Hospital Coaldale, PA
- St Luke's Hospital - Carbon Campus Lehighton, PA
Medical groups
- St Lukes Physician Group Inc (2,198 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 513
- Services billed
- 1,276
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 333 | 190 |
| Established patient office or other outpatient visit, 30-39 minutes | 268 | 171 |
| Test to examine how well the lungs exchange gases | 133 | 133 |
| Test to determine lung volumes using sensors | 124 | 124 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 120 | 120 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 111 | 109 |
| Test for exercise-induced lung stress | 75 | 70 |
| Critical care, first 30-74 minutes | 63 | 34 |
| Established patient office or other outpatient visit, 40-54 minutes | 54 | 44 |
| New patient office or other outpatient visit, 45-59 minutes | 38 | 38 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Fountain Hill, PA | 138 |
| Prednisone Other prescribers in Fountain Hill, PA | 91 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Fountain Hill, PA | 84 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Fountain Hill, PA | 44 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Fountain Hill, PA | 35 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Fountain Hill, PA | 33 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Fountain Hill, PA | 30 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Fountain Hill, PA | 21 |
| Ofev (nintedanib esylate) | 19 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Fountain Hill, PA | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 32 payments worth $17,705 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16,886 |
|---|---|
| United Therapeutics Corporation | $711 |
| Insmed, Inc. | $108 |
| Consulting Fee | $9,848 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,220 |
| Travel and Lodging | $2,826 |
| Food and Beverage | $1,812 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 9, 2025 | Consulting Fee | $5,200 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 23, 2025 | Consulting Fee OFEV · RESPIRATORY | $4,648 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) OFEV · RESPIRATORY | $3,220 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jun 10, 2025 | Travel and Lodging OFEV · RESPIRATORY · travel to Nashville, TN · in-kind | $816 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jun 11, 2025 | Travel and Lodging OFEV · RESPIRATORY · travel to Nashville, TN · in-kind | $774 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 14, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $582 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 2, 2025 | Travel and Lodging OFEV · RESPIRATORY · travel to Nashville, TN · in-kind | $258 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 15, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $226 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 9, 2025 | Travel and Lodging travel to Nashville, TN · in-kind | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 13, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $30.11 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $125,765 in research payments for these studies, mostly to the institutions running them.
- Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
United Therapeutics Corporation · Completed · NCT05776225 - DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
United Therapeutics Corporation · Recruiting · NCT06388421
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.